LSTA
Lisata Therapeutics, Inc. (LSTA) Management Analysis (2026)
Overall Score
Execution
Management is not demonstrating operating leverage, with TTM operating margin at -164.27% and EBITDA margin at -160.07%.
Revenue efficiency remains extremely poor, with asset turnover at 0.01 and working capital turnover at 0.01.
Cash generation is negative, with TTM free cash flow per share at -1.35 and operating cash flow per share at -1.35.
Capital Allocation
The balance sheet is currently debt-light, with debt-to-assets and debt-to-equity both at 0.0.
However, the company is not creating value from capital, with ROIC at -1.99% and ROE at -1.14%.
Liquidity is adequate in the near term, with a current ratio of 3.69 and cash ratio of 3.50.
Incentives & Governance
No recent news or disclosures indicate a change in management incentives or governance quality.
The operating profile suggests management is still under pressure to improve profitability and cash discipline.
There is no evidence this month of a governance catalyst or accountability improvement.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Lisata Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

